News and events

  • All
  • Events
  • Press releases
  • Publications
All
  • All
  • Events
  • Press releases
  • Publications

Bio Partnering at JPM — January 9-12, 2023 – San Francisco, CA

ExeVir is a clinical-stage company developing novel antibody therapies that help patients ward off infectious diseases. Our focus is on protecting populations unable to benefit ...
Read More

ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors

ExeVir is pleased to announce today the appointment of Dr Jeanne Bolger as Chair to the Board of Directors. Dr. Bolger has over 35 years ...
Read More

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a ...
Read More

ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a ...
Read More

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to ...
Read More